Novo Nordisk A/s

Novo Nordisk Healthcare Ag

Nils Langeland Johansen

Kjeld Madsen

Jesper F Lau

Bernd Peschke

Thomas Kruse Hansen

Henrik Sune Andersen

Michael Ankersen

Carsten Behrens

Jens Buchardt

Henning Tho Slashedgersen

Behrend Friedrich Lundt

Birgit Sehested Hansen

Leif Noerskov-Lauritsen

Rolf Hohlweg

Ole Hvilsted Olsen

Uffe Bang Olsen

Patrick William Garibay

Lars Thim

Niels Christian Kaarsholm

Leif Hoejslet Christensen

Ulrich Sensfuss

Mikael Kofod-Hansen

Henning Ralf Stennicke

Florencio Zaragoza Dörwald

Jeppe Sturis

Birgitte Schjellerup Wulff

Peter H Andersen

Susanne Bang

Magali Zundel

Birgitte Koch Michelsen

Peter Thygesen

Søren Østergaard

Henning Thogersen

Anette Sams Nielsen

Stefan Lutz Richter

Christian Thomsen

Philip Just Larsen

Joel Martin

Sonja Bak

Mark Scheideler

Leif Norskov-Lauritsen

Annette Hansen

Emiliano Clo

Henrik Sune Ramirez-Andersen

Magali A Zundel

Niels Peter Fiil

Kilian Waldemar Conde-Frieboes

Emiliano ClÓ

Henrik Sune RAMÍREZ-Andersen

Leif NØRSKOV-Lauritsen

Jing Su

The invention relates to protein conjugates and in particular conjugates of more than two protein or polypeptides. The compounds include a trivalent linker moiety that enables efficient production of desired products.

Protein conjugates

Novel GLP-1 compounds and their therapeutic use.

GLP-1 compounds

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.

Growth hormones with prolonged in-vivo efficacy

The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.

Conjugated proteins with prolonged in vivo efficacy

The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.

The present invention relates generally to a novel method of introducing property modifying groups to a protein. In particular, the present invention relates to the derivatization of lysine residues, as well as new conjugates of growth hormones with improved pharmacological properties, and methods for their preparation and use in therapy.

Method for selectively modifying a protein via transglutaminase catalyzed reaction

Methods for the selective conjugation of peptides which comprises an enzymatic incorporation of a functional group at the C-terminal end of a peptide followed by reaction with a second compound comprising the moiety to be conjugated to the peptide, wherein said second compound comprises a functional group which selectively reacts with the incorporated functional group.

Selectively conjugated peptides and methods of making the same

Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-Rcomprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases.

Melanocortin receptor agonists

The present invention relates to novel human coagulation Factor VII/VIIa proteins having coagulant potential/activity as well as pharmaceutical compositions comprising the proteins, uses thereof, and methods of treatment therewith. In particular, the present invention relates to novel, semi synthetic analogues of human coagulation Factor VII and VIIa (FVII and FVIIa) as well as to a method of their production.

Hybrid molecules having Factor VII/VIIa activity

The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

GLP-2 compounds, formulations, and uses thereof

The present invention relates to compounds, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone.

Compounds with growth hormone releasing properties

Compounds of the general formula I ##STR1## compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are described.

There are disclosed novel synthetic peptides of formula (I) ##STR1## where A, B, D, E, F, G, J, m, n, and p are defined in the specification. Compounds of formula (I) promote the release of growth hormone in humans and animals. Growth promoting compositions containing such compounds of formula (I) as the active ingredient, methods of stimulating the release of growth hormone, and the use of such compounds of formula (I) are also disclosed.

The present invention relates to a method of treating migraine, non-insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation and/or vasomotor disturbances. This method utilizes a hexapeptide of formula (I)

Method of treating hot flushes with hexapeptides

Growing community of inventors

Koebenhavn OE, Denmark

Nils Langeland Johansen